Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joachim Drevs

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Head & Neck|August 31, 2002
Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinomaJarrod J Homer, John Greenman, Joachim Drevs, et al.
Onkologie|March 20, 2009
Molecular targeted therapies for solid tumors: management of side effectsViktor Grünwald, Jens Soltau, Philipp Ivanyi, et al.
International Journal of Molecular Sciences|November 11, 2011
Biomarkers in tumor angiogenesis and anti-angiogenic therapyAndreas Pircher, Wolfgang Hilbe, Isabel Heidegger, et al.
Neuroradiology|January 15, 2005
Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot studyJoachim Klisch, Ralf Kubalek, Kai M Scheufler, et al.
Anticancer Research|January 2, 2010
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinomaMichael Medinger, Norbert Esser, Ute Zirrgiebel, et al.
Archiv Der Pharmazie|October 8, 2005
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigenFelix Kratz, Ahmed Mansour, Jens Soltau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinClemens Unger, Brigitte Häring, Michael Medinger, et al.
Cancer Treatment and Research Communications|June 24, 2025
Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary resultsJoachim Drevs, Mandeep Singh Malhotra, Huseyin Sahinbas, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2004
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose studyKlaus Mross, Bernward Niemann, Ulrich Massing, et al.
Anticancer Research|January 31, 2025
Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal CancerJoachim Drevs, Mandeep Singh Malhotra, Huseyin Sahinbas, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Head & Neck|August 31, 2002
Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinomaJarrod J Homer, John Greenman, Joachim Drevs, et al.
Onkologie|March 20, 2009
Molecular targeted therapies for solid tumors: management of side effectsViktor Grünwald, Jens Soltau, Philipp Ivanyi, et al.
International Journal of Molecular Sciences|November 11, 2011
Biomarkers in tumor angiogenesis and anti-angiogenic therapyAndreas Pircher, Wolfgang Hilbe, Isabel Heidegger, et al.
Neuroradiology|January 15, 2005
Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot studyJoachim Klisch, Ralf Kubalek, Kai M Scheufler, et al.
Anticancer Research|January 2, 2010
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinomaMichael Medinger, Norbert Esser, Ute Zirrgiebel, et al.
Archiv Der Pharmazie|October 8, 2005
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigenFelix Kratz, Ahmed Mansour, Jens Soltau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinClemens Unger, Brigitte Häring, Michael Medinger, et al.
Cancer Treatment and Research Communications|June 24, 2025
Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary resultsJoachim Drevs, Mandeep Singh Malhotra, Huseyin Sahinbas, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2004
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose studyKlaus Mross, Bernward Niemann, Ulrich Massing, et al.
Anticancer Research|January 31, 2025
Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal CancerJoachim Drevs, Mandeep Singh Malhotra, Huseyin Sahinbas, et al.
Pageof 4